 |
| |
| Feb-02-18 | Initiated |
Lake Street |
Buy |
$8 |
|
| Mar-31-17 | Initiated |
Raymond James |
Outperform |
$6 |
|
| Sep-23-16 | Initiated |
Ladenburg Thalmann |
Buy |
|
|
| Feb-19-16 | Initiated |
Chardan Capital Markets |
Buy |
$5 |
|
| Dec-22-15 | Initiated |
Oppenheimer |
Outperform |
$10 |
|
| Dec-19-11 | Upgrade |
WBB Securities |
Buy → Strong Buy |
$8 |
|
| Nov-16-11 | Upgrade |
WBB Securities |
Speculative Buy → Buy |
$6 → $8 |
|
| Aug-11-11 | Initiated |
WBB Securities |
Speculative Buy |
$6 |
|
| Jan-06-11 | Initiated |
BioLogic Equity Research |
Sell |
$2 |
|
|
|
| Apr-26-18 07:00AM | BioTime to Announce First Quarter 2018 Results on May 10, 2018 Business Wire |
| Apr-16-18 07:00AM | Data from BioTimes OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018 Business Wire |
| Apr-10-18 07:41AM | BioTime (BTX): Moving Average Crossover Alert Zacks +5.06% |
| Apr-09-18 08:00AM | Data from BioTimes OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit Business Wire |
| Mar-27-18 07:00AM | BioTime Announces Cash Sale of Ascendance Biotechnology Business Wire |
| Mar-21-18 07:40AM | Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin ACCESSWIRE |
| Mar-16-18 01:20PM | Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT Thomson Reuters StreetEvents +9.84% |
| Mar-15-18 05:35PM | BioTime reports 4Q loss Associated Press -8.30% |
| 04:05PM | BioTime Reports Fourth Quarter and Fiscal 2017 Results Business Wire |
| 12:00PM | BioTime, Inc. to Host Earnings Call ACCESSWIRE |
| 10:44AM | BioTime Q4 Earnings Outlook Benzinga |
| Mar-14-18 08:38AM | BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session Zacks |
| 08:10AM | Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire |
| Mar-13-18 08:00AM | BioTime Submits CE Mark Application for European Approval of Renevia® Business Wire +5.99% |
| Mar-07-18 08:00AM | BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial Business Wire |
| Mar-05-18 08:00AM | BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018 Business Wire |
| Mar-01-18 08:00AM | AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 Business Wire |
| Feb-28-18 08:00AM | BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference Business Wire |
| Feb-26-18 07:00AM | BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs Business Wire |
| Feb-22-18 07:00AM | BioTime Appoints Cavan Redmond to Its Board of Directors Business Wire |
| Feb-15-18 07:00AM | Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 Business Wire |
| Feb-07-18 07:00AM | BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018 Business Wire |
| Jan-29-18 07:00AM | Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference Business Wire +7.27% |
| Jan-23-18 07:00AM | BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018 Business Wire |
| Jan-22-18 07:00AM | BioTime Announces Clinical and Corporate Milestone Targets for 2018 Business Wire |
| Jan-18-18 07:00AM | AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on Stem Cell Innovations That Will Change the World Business Wire |
| Jan-17-18 07:00AM | BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate Business Wire |
| Jan-05-18 04:30PM | AgeX Therapeutics to Present at Biotech Showcase Annual Conference Business Wire |
| Jan-02-18 07:00AM | AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer Business Wire +6.51% |
| Dec-29-17 11:38AM | ETFs with exposure to BioTime, Inc. : December 29, 2017 Capital Cube |
| Dec-20-17 07:49AM | Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys Zacks |
| 07:00AM | BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 Business Wire |
| Dec-19-17 06:23AM | Try Rising P/E Investing With 5 Top-Ranked Stocks Zacks |
| Dec-18-17 02:59PM | ETFs with exposure to BioTime, Inc. : December 18, 2017 Capital Cube |
| Dec-07-17 01:06PM | ETFs with exposure to BioTime, Inc. : December 7, 2017 Capital Cube |
| Dec-05-17 09:35AM | Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys Zacks |
| 08:53AM | BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017 Capital Cube |
| Dec-04-17 08:00AM | Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference Business Wire |
| 07:00AM | AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NC Business Wire |
| Dec-01-17 09:33AM | Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime Zacks |
| Nov-30-17 08:20AM | 5 Affordable Breakout Stocks Offering Excellent Returns Zacks |
| 07:00AM | Data from BioTimes Renevia® Program to Be Presented at IFATS Conference Business Wire |
| Nov-29-17 02:03AM | BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017 Capital Cube |
| Nov-28-17 01:37PM | BioTime, Inc. Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017 Capital Cube |
| Nov-27-17 07:30AM | BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017 Capital Cube |
| Nov-15-17 11:13AM | BioTime, Inc.: Trading close to its 50 day moving average. Good buy? Capital Cube |
| 08:00AM | BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO Business Wire |
| Nov-14-17 12:41AM | Edited Transcript of BTX earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents |
| Nov-13-17 07:00AM | BioTime to Participate in Upcoming Conferences Business Wire -5.08% |
| Nov-10-17 11:58AM | ETFs with exposure to BioTime, Inc. : November 10, 2017 Capital Cube +13.78% |
| Nov-09-17 04:59PM | BioTime beats 3Q profit forecasts Associated Press |
| 04:05PM | BioTime Reports Third Quarter Results and Recent Corporate Accomplishments Business Wire |
| 02:40PM | Edited Transcript of BTX earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents |
| 12:25PM | Is It Time To Buy BioTime Inc (BTX)? Simply Wall St. |
| Nov-08-17 07:00AM | AgeX Therapeutics VP of New Technology Discovery Aubrey de Grey to Serve on Aging & Longevity Panel at FT Global Pharmaceutical and Biotechnology Conference, November 9-10 in London Business Wire |
| Nov-02-17 12:00AM | BioTime to Participate in the Jefferies 2017 London Healthcare Conference Business Wire |
| Oct-26-17 10:22AM | ETFs with exposure to BioTime, Inc. : October 26, 2017 Capital Cube |
| 07:00AM | AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economists Conference The Business of Longevity: Health Innovation for an Ageing World October 27 in Hong Kong Business Wire |
| Oct-24-17 07:00AM | BioTime to Announce Third Quarter 2017 Results on November 9, 2017 Business Wire |
| Oct-18-17 03:03AM | BioTime, Inc. is trading below its 50 day moving average : BTX-US : October 18, 2017 Capital Cube |
| Oct-17-17 04:05PM | BioTime, Inc. Announces Closing of Public Offering and Underwriters Full Exercise of Over-Allotment Option Business Wire |
| Oct-13-17 09:15AM | BioTime, Inc. Announces Pricing of $25.0 Million Public Offering of Common Stock Business Wire |
| 07:10AM | Corporate News Blog - BioTime to Sublicense Hystem(R) to Processa Pharma for Developing Drug Delivery Platforms ACCESSWIRE |
| Oct-12-17 04:05PM | BioTime, Inc. Announces Proposed Public Offering of Common Stock Business Wire |
| Oct-11-17 08:00AM | BioTime Announces First Patient in U.S. Clinical Trial Treated for Facial Volume Deficit Business Wire |
| 07:00AM | BioTime and Processa Announce Their Intention to Enter into a HyStem® Sublicense for Drug Delivery Business Wire |
| Oct-04-17 10:37AM | ETFs with exposure to BioTime, Inc. : October 4, 2017 Capital Cube |
| Oct-03-17 07:00AM | BioTime to Present at the Cell and Gene Meeting on the Mesa Business Wire |
| Sep-26-17 07:00AM | BioTime Announces Positive Secondary and Additional Positive Long-Term Data from the Renevia® Pivotal Trial Business Wire |
| Sep-25-17 07:00AM | BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders Business Wire |
| Sep-22-17 11:05AM | ETFs with exposure to BioTime, Inc. : September 22, 2017 Capital Cube |
| 09:00AM | BioTime - A Multi-Faceted Regenerative Medicine Company ACCESSWIRE |
| Sep-21-17 12:10PM | BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 Capital Cube |
| 10:16AM | BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : September 21, 2017 Capital Cube |
| 07:00AM | BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum Business Wire |
| 07:00AM | AgeX Therapeutics CEO Michael D. West to Participate in Fireside Chat with J. Craig Venter at the Cell & Gene Therapy CEO Forum Business Wire |
| 03:09AM | BioTime, Inc. is trading above its 50 day moving average : BTX-US : September 21, 2017 Capital Cube |
| Sep-20-17 07:00AM | BioTime to Present at the Ladenburg Thalmann 2017 Healthcare Conference Business Wire |
| 07:00AM | BioTime to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire |
| Sep-18-17 07:00AM | BioTime Awarded Grant from the NIH Business Wire |
| Sep-14-17 05:43PM | Two Key BioTime Patents Providing Protection to OpRegen® Remain Upheld Business Wire |
| Sep-11-17 09:55PM | ETFs with exposure to BioTime, Inc. : September 12, 2017 Capital Cube |
| Sep-08-17 08:58PM | BioTime, Inc. :BTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 9, 2017 Capital Cube |
| 07:00AM | BioTime to Present at the Rodman & Renshaw Annual Global Investment Conference Business Wire |
| Sep-05-17 07:00AM | BioTime to Present at the LD Micro San Francisco Summit Business Wire |
| Sep-01-17 09:48AM | BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : September 1, 2017 Capital Cube |
| Aug-28-17 07:00AM | BioTime to Present Data at the Military Health System Research Symposium Business Wire |
| Aug-17-17 07:00AM | AgeX Therapeutics Closes $10 Million Capital Raise Business Wire |
| Aug-14-17 07:00AM | BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD Business Wire |
| Aug-09-17 07:00AM | AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival Business Wire |
| Aug-04-17 02:34AM | BioTime reports 2Q loss Associated Press |
| Aug-02-17 04:10PM | BioTime Reports Second Quarter Results and Recent Corporate Accomplishments Business Wire |
| 10:00AM | Investor Network: BIOTIME INC to Host Earnings Call ACCESSWIRE |
| 08:30AM | AgeX Therapeutics Obtains $10 Million in Capital and Commences Operations Business Wire |
| Jul-31-17 05:42PM | BioTime, Inc. Value Analysis (NYSE MKT:BTX) : July 31, 2017 Capital Cube |
| Jul-25-17 04:30PM | BioTime Receives DSMB Approval to Start Third Patient Cohort in Clinical Trial for Dry-AMD; Commences Patient Enrollment in the US Business Wire |
| Jul-20-17 07:00AM | BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017 Business Wire |
| Jul-19-17 07:00AM | Data From BioTimes Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting Business Wire |
| Jul-18-17 07:00AM | BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City Business Wire |
| Jul-14-17 08:29AM | BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : July 14, 2017 Capital Cube |
|
|
|
|
| BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MOHANTY ADITYA P. | Co-Chief Executive Officer | Apr 10 | Option Exercise | 0.00 | 4,688 | 0 | 99,940 | Apr 12 08:39 PM | | WEST MICHAEL D | Co-Chief Executive Officer | Apr 10 | Option Exercise | 0.00 | 1,563 | 0 | 886,278 | Apr 12 09:00 PM | | WEST MICHAEL D | Co-Chief Executive Officer | Jan 10 | Option Exercise | 0.00 | 1,562 | 0 | 885,401 | Jan 12 08:30 PM | | MOHANTY ADITYA P. | Co-Chief Executive Officer | Jan 10 | Option Exercise | 0.00 | 4,687 | 0 | 97,309 | Jan 12 09:17 PM | | BROADWOOD PARTNERS, L.P. | Director | Oct 13 | Buy | 2.60 | 2,692,307 | 6,999,998 | 29,971,561 | Oct 17 05:58 PM | | WEST MICHAEL D | Co-Chief Executive Officer | Oct 10 | Option Exercise | 0.00 | 1,563 | 0 | 884,427 | Oct 12 07:35 PM | | MOHANTY ADITYA P. | Co-Chief Executive Officer | Oct 10 | Option Exercise | 0.00 | 4,688 | 0 | 94,384 | Oct 12 09:35 PM | | SKIBSTED RUSSELL | Chief Financial Officer | Aug 23 | Buy | 2.64 | 2,000 | 5,285 | 2,000 | Aug 25 04:33 PM | | BROADWOOD PARTNERS, L.P. | Director | Aug 22 | Buy | 2.60 | 10,000 | 25,955 | 27,279,254 | Aug 24 06:58 PM | | WEST MICHAEL D | Co-Chief Executive Officer | Aug 22 | Buy | 2.60 | 2,000 | 5,198 | 882,864 | Aug 23 07:23 PM | | ANDREWS DEBORAH J | Director | Aug 21 | Buy | 2.50 | 2,396 | 5,990 | 8,396 | Aug 23 06:31 PM | | Patton Stephana Eilene | General Counsel | Aug 21 | Buy | 2.58 | 7,500 | 19,376 | 7,500 | Aug 22 08:43 PM | | MOHANTY ADITYA P. | Co-Chief Executive Officer | Aug 21 | Buy | 2.50 | 7,500 | 18,750 | 89,696 | Aug 22 08:22 PM | | BROADWOOD PARTNERS, L.P. | Director | Jul 31 | Buy | 2.80 | 150,000 | 420,000 | 27,269,254 | Aug 02 06:37 PM | | KINGSLEY ALFRED D | See Remarks | Jul 31 | Sale | 2.80 | 150,000 | 420,000 | 5,781,555 | Aug 02 06:27 PM | | MOHANTY ADITYA P. | Co-Chief Executive Officer | Jul 10 | Option Exercise | 0.00 | 4,687 | 0 | 83,958 | Jul 12 07:26 PM | | WEST MICHAEL D | Co-Chief Executive Officer | Jul 10 | Option Exercise | 0.00 | 1,562 | 0 | 881,451 | Jul 12 07:21 PM | | ANDREWS DEBORAH J | Director | Jun 16 | Buy | 2.95 | 2,000 | 5,900 | 6,000 | Jun 21 08:19 PM | | ANDREWS DEBORAH J | Director | May 16 | Buy | 3.21 | 2,000 | 6,410 | 4,000 | May 17 08:52 PM |
|
|
|
|
|
|
